NeuroSense Therapeutics Ltd. [NRSN] is 1.63% higher this YTD. Is it still time to buy?

Related

NeuroSense Therapeutics Ltd. [NASDAQ: NRSN] traded at a high on 06/27/22, posting a 47.06 gain after which it closed the day’ session at $2.50. The company report on June 27, 2022 that NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in NeuroSense’s Phase IIa study with PrimeC.

New biomarker data in people with ALS validates NeuroSense’s clinical strategy.

The results of the trading session contributed to over 99867434 shares changing hands. Over the past one week, the price volatility of NeuroSense Therapeutics Ltd. stands at 11.93% while the volatility over the past one month is 9.34%.

The market cap for NRSN stock reached $28.82 million, with 10.99 million shares outstanding and 6.70 million shares in the current float. Compared to the average trading volume of 470.03K shares, NRSN reached a trading volume of 99867434 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about NeuroSense Therapeutics Ltd. [NRSN]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NRSN shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NRSN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for NeuroSense Therapeutics Ltd. is set at 0.22 The Price to Book ratio for the last quarter was 2.27, with the Price to Cash per share for the same quarter was set at 1.19.

How has NRSN stock performed recently?

NeuroSense Therapeutics Ltd. [NRSN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 50.60. With this latest performance, NRSN shares gained by 86.57% in over the last four-week period, additionally sinking by -14.82% over the last 6 months.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NRSN stock in for the last two-week period is set at 80.51, with the RSI for the last a single of trading hit 90.85, and the three-weeks RSI is set at 69.17 for NeuroSense Therapeutics Ltd. [NRSN]. The present Moving Average for the last 50 days of trading for this stock 1.6300, while it was recorded at 1.8400 for the last single week of trading.

NeuroSense Therapeutics Ltd. [NRSN]: Deeper insight into the fundamentals

Return on Equity for this stock declined to -83.62, with Return on Assets sitting at -66.19.

NeuroSense Therapeutics Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.40 and a Current Ratio set at 11.40.

Insider trade positions for NeuroSense Therapeutics Ltd. [NRSN]

There are presently around $0 million, or 1.50% of NRSN stock, in the hands of institutional investors. The top three institutional holders of NRSN stocks are: IKARIAN CAPITAL, LLC with ownership of 100,000, which is approximately New of the company’s market cap and around 45.49% of the total institutional ownership; JANE STREET GROUP, LLC, holding 43,498 shares of the stock with an approximate value of $74000.0 in NRSN stocks shares; and BOOTHBAY FUND MANAGEMENT, LLC, currently with $21000.0 in NRSN stock with ownership of nearly New of the company’s market capitalization.

Positions in NeuroSense Therapeutics Ltd. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 7 institutional holders increased their position in NeuroSense Therapeutics Ltd. [NASDAQ:NRSN] by around 166,803 shares. Additionally, 5 investors decreased positions by around 152,777 shares, while 0 investors held positions by with 150,593 shares. The mentioned changes placed institutional holdings at 168,987 shares, according to the latest SEC report filing. NRSN stock had 7 new institutional investments in for a total of 166,803 shares, while 3 institutional investors sold positions of 145,620 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]